The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.
Eagerly pursuing all the latest fads and trends.